Cougar Biotechnology, Inc. (NASDAQ: CGRB)

Cougar Biotechnology, Inc. (NASDAQ: CGRB), a Los Angeles-based biotechnology company, was established to in-license and develop clinical stage drugs. Their specific focus is on the field of oncology. The company’s portfolio includes CB7630, which is being tested in a Phase III clinical trial in prostate cancer; CB3304, which is in a Phase I trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types. For further information, visit the Company’s web site at www.cougarbiotechnology.com.